Opportunity remains despite regulatory and access obstacles.
Natalya Stone
Advertisement
Natalya Stone is a consultant within the life sciences practice at Guidehouse
Articles by Natalya Stone
Advertisement
Latest Updated Articles
The JAKs Journey Offers Valuable Lessons for InnovatorsFebruary 17th 2022
Advertisement
Advertisement
Trending on PharmExec
1
Boehringer Ingelheim Expands Immunology Pipeline With Preclinical Antibody Licensing Deal
2
Marty Makary Out as FDA Commissioner: Report
3
The Insight Gap: Biopharma’s Hidden Risk in the Race Against the Patent Cliff
4
From Consulting to Venture Capital: A Q&A with Gibb Witham, President of Hack The Box
5